Analysts anticipate HCA Healthcare will report Q3 2026 consensus revenue of $19.33 billion and EPS of $6.74, as the stock trades at $469.61 compared to a $476.00 average price target.
Investors are primarily focused on the significant "payer mix shift" as millions of patients migrate from ACA health insurance exchanges to uninsured or lower-tier coverage.
This transition has pressured margins and recently forced management to lower its full-year 2026 profit guidance. Additionally, analysts are closely monitoring same-facility equivalent admissions for signs of volume stability to offset a decline in high-margin elective surgical procedures.